238 Trial – Nivolumab as Standard for Melanoma Therapeutics Available for Relapsed Immunotherapy

Omid Hamid MD
Chief, Translational Research/Immuno-Oncology
Director explains, 238 Trial – Nivolumab as Standard for Melanoma Therapeutics Available for Relapsed Immunotherapy at the 2018 Oncology Summit in Huntington Beach, CA